Yorktown Management & Research Company’s CRISPR Therapeutics CRSP Stock Holding History

Yorktown Management & Research Company’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,800	Closed	-$364K	–	231
2021 Q4	$364K	Hold	4,800	–	–	0.25%	159
2021 Q3	$537K	Hold	4,800	–	–	0.4%	86
2021 Q2	$777K	Sell	4,800 -3,600	-43%	-$438K	0.61%	33
2021 Q1	$1.02M	Sell	8,400 -200	-2%	-$30.2K	0.85%	22
2020 Q4	$1.32M	Hold	8,600	–	–	1.19%	11
2020 Q3	$719K	Buy	8,600 +1,400	+19%	+$124K	0.67%	22
2020 Q2	$529K	Buy	+7,200	New	+$421K	0.47%	38

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Yorktown Management & Research Company's CRSP Position: Q1 2022 in Review

Yorktown Management & Research Company sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 4,800 shares — an estimated $364K sold.

Yorktown Management & Research Company first reported a position in CRSP in Q2 2020 and held it in 7 quarters. The position peaked at $1.32M in Q4 2020. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Yorktown Management & Research Company reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Yorktown Management & Research Company sold 4,800 CRISPR Therapeutics shares in Q1 2022, an estimated $364K.
Yorktown Management & Research Company first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 7 quarters.
Yorktown Management & Research Company's CRISPR Therapeutics position peaked at $1.32M in Q4 2020.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Yorktown Management & Research Company's 13F filing for Q1 2022, filed 29 Apr 2022.